{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:57Z","timestamp":1786979937699,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T00:00:00Z","timestamp":1719273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Steroid-refractory chronic graft-versus-host disease (cGvHD) is associated with significant morbidity and mortality, with ruxolitinib being the first drug approved for its treatment. We retrospectively analyzed the safety and efficacy of ruxolitinib for treatment of cGvHD at our center between 07\/2015 and 12\/2022 and identified 48 patients receiving ruxolitinib as second (18\/48) or advanced (30\/48) treatment line. Ruxolitinib was started on median day 340 (range 119\u2013595) after cGvHD onset; median duration of administration was 176 (range, 79\u2013294) days with 16\/48 patients continuing treatment at last follow-up. National Institutes of Health organ grading and the intensity of immunosuppression were assessed at the start of ruxolitinib treatment and repeated after 1, 3, 6, and 12 months. Response assessment was terminated at the start of any additional new immunosuppressant treatment. The median time of follow-up was 582 (range, 104\u20131161) days. At the primary analysis after six months on ruxolitinib treatment, the overall response rate was 33%, and failure-free survival was 58%. Infectious adverse events\u2009\u2265\u2009CTCAE grade III were observed in 10\/48 patients. The response rate was not associated with the severity of cGvHD, number of previous treatment lines, or number of additional agents combined with ruxolitinib applying a univariate regression model. At the time of the 12-month follow-up, four patients experienced recurrence of the underlying malignancy and two patients had experienced non-relapse-related mortality. Overall, ruxolitinib was relatively well-tolerated and showed outcomes comparable to the REACH3 trial in a heavily pretreated patient population.<\/jats:p>","DOI":"10.1007\/s00277-024-05697-w","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T01:01:31Z","timestamp":1719277291000},"page":"3755-3764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of ruxolitinib in the treatment of chronic graft-versus-host disease: a retrospective analysis"],"prefix":"10.1007","volume":"103","author":[{"given":"Alexander","family":"Denk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Mittermaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Fante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"G\u00fcne\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Edinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,25]]},"reference":[{"issue":"8","key":"5697_CR1","doi-asserted-by":"publisher","first-page":"2867","DOI":"10.1182\/blood-2006-02-003954","volume":"108","author":"CJ Fraser","year":"2006","unstructured":"Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M, Parker P, Forman S, Weisdorf D, Gurney JG, Baker KS (2006) Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the bone marrow transplant Survivor Study. Blood 108(8):2867\u20132873. https:\/\/doi.org\/10.1182\/blood-2006-02-003954","journal-title":"Blood"},{"issue":"17","key":"5697_CR2","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","volume":"117","author":"J Pidala","year":"2011","unstructured":"Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, Cutler C, Jacobsohn D, Palmer J, Arai S, Jagasia M, Lee SJ (2011) Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the chronic GVHD Consortium. Blood 117(17):4651\u20134657. https:\/\/doi.org\/10.1182\/blood-2010-11-319509","journal-title":"Blood"},{"issue":"3","key":"5697_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.bbmt.2015.10.018","volume":"22","author":"M Arora","year":"2016","unstructured":"Arora M, Cutler CS, Jagasia MH, Pidala J, Chai X, Martin PJ, Flowers ME, Inamoto Y, Chen GL, Wood WA, Khera N, Palmer J, Duong H, Arai S, Mayer S, Pusic I, Lee SJ (2016) Late Acute and Chronic Graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl 22(3):449\u2013455. https:\/\/doi.org\/10.1016\/j.bbmt.2015.10.018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"25","key":"5697_CR4","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, Horowitz MM, Jones RJ, Holtan SG, BMT CTN 1703 Investigators (2023) N Engl J Med 388(25):2338\u20132348. https:\/\/doi.org\/10.1056\/NEJMoa2215943. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis","journal-title":"N Engl J Med"},{"issue":"1","key":"5697_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kr\u00f6ger","year":"2016","unstructured":"Kr\u00f6ger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, P\u00e9rez de Oteiza J, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, V\u00f6lp A, Ayuk F, Ruutu T, Bonifazi F (2016) Antilymphocyte Globulin for Prevention of Chronic Graft-versus-host disease. N Engl J Med 374(1):43\u201353. https:\/\/doi.org\/10.1056\/NEJMoa1506002","journal-title":"N Engl J Med"},{"issue":"26","key":"5697_CR6","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Longo DL, Blazar BR (2017) Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med 377(26):2565\u20132579. https:\/\/doi.org\/10.1056\/NEJMra1703472","journal-title":"N Engl J Med"},{"issue":"1","key":"5697_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2016-06-686618","volume":"129","author":"KPA MacDonald","year":"2017","unstructured":"MacDonald KPA, Hill GR, Blazar BR (2017) Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 129(1):13\u201321. https:\/\/doi.org\/10.1182\/blood-2016-06-686618","journal-title":"Blood"},{"key":"5697_CR8","doi-asserted-by":"publisher","unstructured":"Wolff D, Lawitschka A (2019) Chronic Graft-Versus-Host Disease. In: Carreras E, Dufour C, Mohty M, Kroger N (eds) The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th edn., Cham (CH), pp 331\u2013345. https:\/\/doi.org\/10.1007\/978-3-030-02278-5_44","DOI":"10.1007\/978-3-030-02278-5_44"},{"key":"5697_CR9","doi-asserted-by":"publisher","unstructured":"Wolff D, Gerbitz A, Ayuk F, Kiani A, Hildebrandt GC, Vogelsang GB, Elad S, Lawitschka A, Socie G, Pavletic SZ, Holler E, Greinix H (2010) Consensus Conference on Clinical Practice in Chronic Graft-versus-Host Disease (GVHD): First-Line and Topical Treatment of Chronic GVHD. Biology of Blood and Marrow Transplantation 16 (12):1611\u20131628. https:\/\/doi.org\/10.1016\/j.bbmt.2010.06.015","DOI":"10.1016\/j.bbmt.2010.06.015"},{"issue":"3","key":"5697_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, Palmer J, Weisdorf D, Treister NS, Cheng GS, Kerr H, Stratton P, Duarte RF, McDonald GB, Inamoto Y, Vigorito A, Arai S, Datiles MB, Jacobsohn D, Heller T, Kitko CL, Mitchell SA, Martin PJ, Shulman H, Wu RS, Cutler CS, Vogelsang GB, Lee SJ, Pavletic SZ, Flowers ME (2015) National Institutes of Health Consensus Development Project on Criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and Staging Working Group report. Biol Blood Marrow Transpl 21(3):389\u2013401e381. https:\/\/doi.org\/10.1016\/j.bbmt.2014.12.001","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"5697_CR11","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41409-019-0544-y","volume":"54","author":"L Axt","year":"2019","unstructured":"Axt L, Naumann A, Toennies J, Haen SP, Vogel W, Schneidawind D, Wirths S, Moehle R, Faul C, Kanz L, Axt S, Bethge WA (2019) Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 54(11):1805\u20131814. https:\/\/doi.org\/10.1038\/s41409-019-0544-y","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"5697_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","volume":"385","author":"R Zeiser","year":"2021","unstructured":"Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F (2021) Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med 385(3):228\u2013238. https:\/\/doi.org\/10.1056\/NEJMoa2033122","journal-title":"N Engl J Med"},{"key":"5697_CR13","doi-asserted-by":"publisher","unstructured":"Elli EM, Barat\u00e8 C, Mendicino F, Palandri F, Palumbo GA (2019) Mechanisms underlying the anti-inflammatory and immunosuppressive activity of Ruxolitinib. Front Oncol 9. https:\/\/doi.org\/10.3389\/fonc.2019.01186","DOI":"10.3389\/fonc.2019.01186"},{"issue":"7","key":"5697_CR14","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1182\/blood-2013-03-484642","volume":"122","author":"A Heine","year":"2013","unstructured":"Heine A, Held SAE, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P (2013) The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood 122(7):1192\u20131202. https:\/\/doi.org\/10.1182\/blood-2013-03-484642","journal-title":"Blood"},{"issue":"2","key":"5697_CR15","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1634\/theoncologist.2019-0627","volume":"25","author":"D Przepiorka","year":"2020","unstructured":"Przepiorka D, Luo L, Subramaniam S, Qiu J, Gudi R, Cunningham LC, Nie L, Leong R, Ma L, Sheth C, Deisseroth A, Goldberg KB, Blumenthal GM, Pazdur R (2020) FDA approval Summary: Ruxolitinib for treatment of steroid-refractory Acute graft-versus-host disease. Oncologist 25(2):e328\u2013e334. https:\/\/doi.org\/10.1634\/theoncologist.2019-0627","journal-title":"Oncologist"},{"key":"5697_CR16","unstructured":"Wolf A, Masow J, Billings M (2022) Novartis receives European Commission approval for Jakavi\u00ae to be the first post-steroid treatment for acute and chronic graft-versus-host disease. Novartis.com"},{"issue":"8","key":"5697_CR17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1093\/oncolo\/oyac076","volume":"27","author":"DJ Martini","year":"2022","unstructured":"Martini DJ, Chen Y-B, DeFilipp Z (2022) Recent FDA approvals in the treatment of graft-versus-host disease. Oncologist 27(8):685\u2013693. https:\/\/doi.org\/10.1093\/oncolo\/oyac076","journal-title":"Oncologist"},{"issue":"5","key":"5697_CR18","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41409-018-0370-7","volume":"54","author":"MA Fante","year":"2018","unstructured":"Fante MA, Holler E, Schmidt B, Wolff D, Ehrl Y, Plentz A (2018) Persistent polyomavirus-associated nephropathy in a patient with GvHD and treatment with the JAK1\/2 inhibitor ruxolitinib. Bone Marrow Transplant 54(5):762\u2013764. https:\/\/doi.org\/10.1038\/s41409-018-0370-7","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"5697_CR19","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1038\/s41409-021-01389-5","volume":"56","author":"D Wolff","year":"2021","unstructured":"Wolff D, Fatobene G, Rocha V, Kr\u00f6ger N, Flowers ME (2021) Steroid-refractory chronic graft-versus-host disease: treatment options and patient management. Bone Marrow Transplant 56(9):2079\u20132087. https:\/\/doi.org\/10.1038\/s41409-021-01389-5","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"5697_CR20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/2040620713489842","volume":"4","author":"C Garnett","year":"2013","unstructured":"Garnett C, Apperley JF, Pavl\u016f J (2013) Treatment and management of graft-versus-host disease: improving response and survival. Therapeutic Adv Hematol 4(6):366\u2013378. https:\/\/doi.org\/10.1177\/2040620713489842","journal-title":"Therapeutic Adv Hematol"},{"issue":"4","key":"5697_CR21","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1182\/blood-2014-08-551994","volume":"125","author":"MED Flowers","year":"2015","unstructured":"Flowers MED, Martin PJ (2015) How we treat chronic graft-versus-host disease. Blood 125(4):606\u2013615. https:\/\/doi.org\/10.1182\/blood-2014-08-551994","journal-title":"Blood"},{"key":"5697_CR22","doi-asserted-by":"publisher","unstructured":"Wang D, Liu Y, Lai X, Chen J, Cheng Q, Ma X, Lin Z, Wu D, Xu Y (2021) Efficiency and toxicity of Ruxolitinib as a salvage treatment for steroid-refractory chronic graft-versus-host disease. Front Immunol 12. https:\/\/doi.org\/10.3389\/fimmu.2021.673636","DOI":"10.3389\/fimmu.2021.673636"},{"issue":"2","key":"5697_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.bbmt.2018.09.003","volume":"25","author":"B Modi","year":"2019","unstructured":"Modi B, Hernandez-Henderson M, Yang D, Klein J, Dadwal S, Kopp E, Huelsman K, Mokhtari S, Ali H, Malki MMA, Spielberger R, Salhotra A, Zain J, Cotliar J, Parker P, Forman S, Nakamura R (2019) Ruxolitinib as Salvage Therapy for Chronic Graft-versus-host disease. Biol Blood Marrow Transplant 25(2):265\u2013269. https:\/\/doi.org\/10.1016\/j.bbmt.2018.09.003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"5697_CR24","doi-asserted-by":"publisher","first-page":"e2034750","DOI":"10.1001\/jamanetworkopen.2020.34750","volume":"4","author":"H Wu","year":"2021","unstructured":"Wu H, Shi J, Luo Y, Tan Y, Zhang M, Lai X, Yu J, Liu L, Fu H, Huang H, Zhao Y (2021) Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-host disease after allogeneic hematopoietic stem cell transplantation. JAMA Netw Open 4(1):e2034750. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.34750","journal-title":"JAMA Netw Open"},{"key":"5697_CR25","doi-asserted-by":"publisher","unstructured":"Xue E, Lorentino F, Pavesi F, Assanelli A, Peccatori J, Bernardi M, Corti C, Ciceri F, Lupo Stanghellini MT (2021) Ruxolitinib for chronic steroid-refractory graft versus host disease: a single center experience. Leuk Res 109. https:\/\/doi.org\/10.1016\/j.leukres.2021.106642","DOI":"10.1016\/j.leukres.2021.106642"},{"issue":"1","key":"5697_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jtct.2021.10.015","volume":"28","author":"S Redondo","year":"2022","unstructured":"Redondo S, Esquirol A, Novelli S, Caballero AC, Garrido A, O\u00f1ate G, L\u00f3pez J, Moreno C, Saavedra S-D, Granell M, Briones J, Sierra J, Martino R, Garc\u00eda-Cadenas I (2022) Efficacy and safety of Ruxolitinib in Steroid-Refractory\/Dependent Chronic Graft-versus-host disease: real-World data and challenges. Transplantation Cell Therapy 28(1):43. e41-43.e45","journal-title":"Transplantation Cell Therapy"},{"issue":"9","key":"5697_CR27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM (2012) A Double-Blind, placebo-controlled trial of Ruxolitinib for Myelofibrosis. N Engl J Med 366(9):799\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1110557","journal-title":"N Engl J Med"},{"issue":"9","key":"5697_CR28","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian J-J, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G (2012) JAK inhibition with Ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366(9):787\u2013798. https:\/\/doi.org\/10.1056\/NEJMoa1110556","journal-title":"N Engl J Med"},{"issue":"1","key":"5697_CR29","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1128\/jvi.01571-06","volume":"81","author":"JR Abend","year":"2007","unstructured":"Abend JR, Low JA, Imperiale MJ (2007) Inhibitory effect of Gamma Interferon on BK Virus Gene expression and replication. J Virol 81(1):272\u2013279. https:\/\/doi.org\/10.1128\/jvi.01571-06","journal-title":"J Virol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05697-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05697-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05697-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T05:14:13Z","timestamp":1724822053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05697-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,25]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["5697"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05697-w","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,25]]},"assertion":[{"value":"14 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the responsible institution and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all patients for being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Daniel Wolff has received honoraria from Mallinckrodt, Neovi, Takedaz, and Novartis. Sibel G\u00fcne\u015f is an employee of Novartis Pharma AG. Matthias Fante received honoraria from Novartis. All other authors have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}